Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 8

1.

Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.

Ham J, Costa C, Sano R, Lochmann TL, Sennott EM, Patel NU, Dastur A, Gomez-Caraballo M, Krytska K, Hata AN, Floros KV, Hughes MT, Jakubik CT, Heisey DA, Ferrell JT, Bristol ML, March RJ, Yates C, Hicks MA, Nakajima W, Gowda M, Windle BE, Dozmorov MG, Garnett MJ, McDermott U, Harada H, Taylor SM, Morgan IM, Benes CH, Engelman JA, Mossé YP, Faber AC.

Cancer Cell. 2016 Feb 8;29(2):159-72. doi: 10.1016/j.ccell.2016.01.002.

2.

MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells.

Altman BJ, Hsieh AL, Sengupta A, Krishnanaiah SY, Stine ZE, Walton ZE, Gouw AM, Venkataraman A, Li B, Goraksha-Hicks P, Diskin SJ, Bellovin DI, Simon MC, Rathmell JC, Lazar MA, Maris JM, Felsher DW, Hogenesch JB, Weljie AM, Dang CV.

Cell Metab. 2015 Dec 1;22(6):1009-19. doi: 10.1016/j.cmet.2015.09.003. Epub 2015 Sep 17.

PMID:
26387865
3.

DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma.

Koomoa DL, Geerts D, Lange I, Koster J, Pegg AE, Feith DJ, Bachmann AS.

Int J Oncol. 2013 Apr;42(4):1219-28. doi: 10.3892/ijo.2013.1835. Epub 2013 Feb 21.

4.

ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth.

Hart LS, Cunningham JT, Datta T, Dey S, Tameire F, Lehman SL, Qiu B, Zhang H, Cerniglia G, Bi M, Li Y, Gao Y, Liu H, Li C, Maity A, Thomas-Tikhonenko A, Perl AE, Koong A, Fuchs SY, Diehl JA, Mills IG, Ruggero D, Koumenis C.

J Clin Invest. 2012 Dec;122(12):4621-34. doi: 10.1172/JCI62973. Epub 2012 Nov 12.

5.

Myc proteins as therapeutic targets.

Gustafson WC, Weiss WA.

Oncogene. 2010 Mar 4;29(9):1249-59. doi: 10.1038/onc.2009.512. Epub 2010 Jan 25.

6.

Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.

Chen Z, Lin Y, Barbieri E, Burlingame S, Hicks J, Ludwig A, Shohet JM.

Neoplasia. 2009 Aug;11(8):753-62.

7.

Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists.

Lestini BJ, Goldsmith KC, Fluchel MN, Liu X, Chen NL, Goyal B, Pawel BR, Hogarty MD.

Cancer Biol Ther. 2009 Aug;8(16):1587-95. Epub 2009 Aug 8.

8.

Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas.

Chayka O, Corvetta D, Dews M, Caccamo AE, Piotrowska I, Santilli G, Gibson S, Sebire NJ, Himoudi N, Hogarty MD, Anderson J, Bettuzzi S, Thomas-Tikhonenko A, Sala A.

J Natl Cancer Inst. 2009 May 6;101(9):663-77. doi: 10.1093/jnci/djp063. Epub 2009 Apr 28.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk